Education Objectives: Chronic Leukemia(s)

Support programs for Chronic Leukemia(s) that:

• Improve competency and performance in recognizing factors that affect the diagnosis, staging, and prognosis of patients with Chronic Leukemia(s).
• Improve competency and performance in the evaluation of the risk-benefit profile of treatments used for Chronic Leukemia(s).
• Provide updates on current treatment guidelines, evidence-based therapeutic algorithms, clinical trial results, and expert clinical perspectives when diagnosing and treating Acute and Chronic Leukemia(s).

Chronic Leukemia Audience Groups: Medical Oncologists, Radiation Oncologists, Hematologist -Oncologists, Surgical Oncologists, Oncology Nurses, Oncology Pharmacists, Medical Directors, and Pharmacy Directors

Education Objectives: Huntington's Disease

• Support education to improve knowledge and awareness of Huntington’s Disease, including genetic factors, disease state pathophysiology, symptoms, and diagnosis of patients, quality of life, psychological issues and movement issues
• Support education to improve knowledge and awareness of the clinical efficacy and safety profile of current and potential treatment options for Huntington’s Disease
• Support education to improve knowledge and awareness of Huntington’s Disease-related chorea and the ability to identify appropriate patients for treatment, and to improve clinical experience and address unmet treatment needs

Huntington's Disease Audience Groups:  Neurologists, Psychiatrists, Nurses, Nurse Practitioners, Physician Assistants, and Pharmacists

Education Objectives: Tardive Dyskinesia

• Support education to improve knowledge and awareness of Tardive Dyskinesia, including disease state pathophysiology, symptom recognition, diagnosis of patients and quality of life
• Support education to improve understanding of differential diagnosis of Hyperkinetic Movement disorders
• Support education to improve knowledge and awareness of conditions and medications known to be associated with Tardive Dyskinesia
• Support education to improve knowledge and awareness of the clinical efficacy and safety profile of current and potential treatment options for Tardive Dyskinesia
• Support education to increase confidence in treating Tardive Dyskinesia including monitoring, managing medication adherence, and improving clinical experience on long term treatment and challenges for optimal outcomes
• Support education to increase competency and confidence in addressing barriers to long-term treatment success with VMAT2 inhibitors and in making appropriate dose adjustments for optimal VMAT2 inhibitor efficacy, safety and medication adherence

Tardive Dyskinesia Audience Groups: Psychiatrists, Neurologists, Nurses, Nurse Practitioners, Physician Assistants, and Pharmacists

Education Objectives: Asthma

Support programs for Asthma that:

• Increase HCP awareness and understanding regarding poor inhaler technique and potential clinical outcomes
• Increase HCP understanding of the correlation between overuse of rescue and asthma control
• Improve HCP competence in identifying patients who are at risk for uncontrolled asthma and asthma exacerbation due to improper inhaler technique and/or poor adherence
• Increase HCP awareness on the use of digital health and technology in the management of asthma
• Increase HCP understanding of how digital technology (e.g., SABA tracking, medication use reminders, symptom recording, inhalation feedback, asthma action plans, etc.) can make an impact on inhaler technique and outcomes in asthma
• Increase awareness of the need for connected/digital respiratory technology and how this might be integrated into everyday patient care

Asthma Audience Groups:  Allergists, Pulmonologists, Immunologists, Primary Care Physicians, Nurses, Pharmacists, Nurse Practitioners, and Physician Assistants

Education Objectives: Non-Hodgkin’s Lymphoma

Support programs for Non-Hodgkin’s Lymphoma that:

• Improve competency and performance in recognizing factors that affect the diagnosis, staging, and prognosis of patients with Non-Hodgkin’s Lymphoma.
• Improve competency and performance in the evaluation of the risk-benefit profile of treatments used for Non-Hodgkin’s Lymphoma.
• Provide updates on current treatment guidelines, evidence-based therapeutic algorithms, clinical trial results, and expert clinical perspectives when diagnosing and treating Non-Hodgkin’s Lymphoma.

Lymphoma Audience Groups: Medical Oncologists, Radiation Oncologists, Hematologist -Oncologists, Surgical Oncologists, Oncology Nurses, Oncology Pharmacists, Medical Directors, and Pharmacy Directors

Education Objectives: Biosimilars

Support programs for Biosimilars that:

• Reinforce the knowledge and competence of oncology professionals in their use of transtuzumab for the treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer
• Reinforce the knowledge and competence of oncology professionals in their use of rituximab for the treatment of non-Hodgkin's lymphoma (NHL) and other B-cell lymphomas.
• Improve the knowledge and awareness of biosimilar products and a description of FDA’s general approach to the development and approval of biosimilar products
• Improve knowledge and awareness of the health economics data of biosimilars with respect to payers, managed care, and formulary-decision making

Biosimilars Audience Groups: Oncology & Rheumatology Professionals, including Physicians, Nurses, Physician Assistants, Pharmacists, Medical Directors, and Pharmacy Directors

Education Objectives: Multiple Sclerosis

Support programs for Multiple Sclerosis that:

• Improve the competency of the Health Care Professional’s (HCP) ability to differentiate the current and emerging MS therapies based on the Mechanism of Action (MOA), short and long term efficacy, safety, and routes of administration of the products
• Provide self-assessment activities to HCPs to measure their knowledge of current research in MS and potential implications on future treatment paradigms and decisions, including individualized treatment plans and research on biomarkers for treatment response

Multiple Sclerosis Audience Groups:  Audience that primarily specializes in the treatment of MS (MS Specialists, Neurologists, etc.) but can also include PCPs, MS Certified Nurses, Nurses, Pharmacists, and Nurse Practitioners, and Physician Assistants